Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

 

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link

 

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

• Target Disease Indication 
• Breast Cancer
• Chronic Lymphocytic Leukemia
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Lupus Nephritis
• Melanoma
• Multiple Myeloma
• Primary Sjögren's Syndrome
• Others 

 

• Target Immune Checkpoint
• B7-H3
• CD38
• CD40
• CD47
• Others

 

• Mechanism of Action
• Inhibitory
• Stimulatory

 

• Therapeutic Modality
• Monoclonal Antibody
• Small Molecule

 

• Type of Therapy 
• Monotherapy 
• Combination Therapy

 

• Route of Administration
• Intravenous
• Subcutaneous
• Others

 

• Key Geographical Regions 
• North America
• Europe
• Asia-Pacific and the Rest of the World 

 

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Current Market Landscape: Clinical and Preclinical Molecules
 

5. Market Landscape: Therapies Targeting Cd47
 

6. Market Landscape: Therapies Targeting 4-1bb
 

7. Clinical Trial Analysis 
 

8. Company Profiles: Next Generation Inhibitors and Stimulators
 

9. Academic Grants Analysis
 

10. Partnerships and Collaborations
 

11. Target Competitiveness Analysis
 

12. Big Pharma Initiatives
 

13. Market Forecast and Opportunity Analysis
 

14. Concluding Remarks

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com